The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology

Annals of Surgical Oncology

Volumn 23, Issue 1, 2016, Pages 290-296

  Ferrone, Cristina R ^a   Ting, David T ^a   Shahid, Mohammed ^a   Konstantinidis, Ioannis T ^a   Sabbatino, Francesco ^a   Goyal, Lipika ^a   Rice Stitt, Travis ^a   Mubeen, Ayesha ^a   Arora, Kshitij ^a   Bardeesey, Nabeel ^a   Miura, John ^b   Gamblin, T Clark ^b   Zhu, Andrew X ^a   Borger, Darrell ^a   Lillemoe, Keith D ^a   Rivera, Miguel N ^a   Deshpande, Vikram ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALBUMINOID; DNA; MESSENGER RNA;

ARTICLE; BILE DUCT; BILE DUCT CARCINOMA; BILE DUCT TUMOR; BLADDER TUMOR; BRANCHED DNA ENHANCED ALBUMIN RNA IN SITU HYBRIDIZATION TECHNOLOGY; BREAST TUMOR; CANCER DIAGNOSIS; CANCER SURVIVAL; COLON TUMOR; CONTROLLED STUDY; DNA HYBRIDIZATION; DNA PROBE; ENDOMETRIUM TUMOR; ESOPHAGUS TUMOR; FIBROBLAST; HUMAN; IN SITU HYBRIDIZATION; KIDNEY TUMOR; KUPFFER CELL; LIVER; LIVER CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; OVARY TUMOR; OVERALL SURVIVAL; PANCREAS TUMOR; STOMACH TUMOR; STROMA; ADENOCARCINOMA; AGED; BILE DUCT NEOPLASMS; CANCER GRADING; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; FOLLOW UP; GENETICS; LIVER NEOPLASMS; MALE; PROCEDURES; PROGNOSIS;

ADENOCARCINOMA; AGED; ALBUMINS; BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; DNA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION; LIVER NEOPLASMS; MALE; NEOPLASM GRADING; PROGNOSIS; RNA, MESSENGER;

EID: 84952628800     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4247-8     Document Type: Article

References (24)

1. Everhart JE, Ruhl CE. Burden of Digestive Diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology. 2009;136:1134–44.
2. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512–22.
3. Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61:1657–69.
4. De Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140–5.
5. Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers. 2013;34:219–28.
6. Tickoo SK, Zee SY, Obiekwe S, et al. Combined hepatocellular-cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol. 2002;26:989.
7. Krishna M, Lloyd RV, Batts KP. Detection of albumin messenger RNA in hepatic and extrahepatic neoplasms: a marker of hepatocellular differentiation. Am J Surg Pathol. 1997;21:147–52.
8. Breborowicz J, Tamaoki T. Detection of messenger RNAs of alpha-fetoprotein and albumin in a human hepatoma cell line by in situ hybridization. Cancer Res. 1985;45:1730–6.
9. Yamaguchi K, Nalesnik MA, Carr BI. In situ hybridization of albumin mRNA in normal liver and liver tumors: identification of hepatocellular origin. Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64:361–5.
10. D’Errico A, Deleonardi G, Fiorentino M, Scoazec JY, Grigioni WF. Diagnostic implications of albumin messenger RNA detection and cytokeratin pattern in benign hepatic lesions and biliary cystadenocarcinoma. Diagn Mol Pathol. 1998;7:289–94.
11. Oliveira AMA, Erickson LAL, Burgart LJL, Lloyd RVR. Differentiation of primary and metastatic clear cell tumors in the liver by in situ hybridization for albumin messenger RNA. Am J Surg Pathol 2000;24:177–82.
12. Zhou D, Conrad C, Xia F, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009;16:425–38.
13. Yan BC, Gong C, Song J, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010;34:1147–54.
14. Voss JS, Holtegaard LM, Kerr SE, et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol. 2013;44:1216–22.
15. Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013;32:3091–100.
16. Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012;43:1552–8.
17. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17:72–9.
18. Muir C. Cancer of unknown primary site. Cancer. 1995;75(1 Suppl):353–6.
19. Daud AI. Removing the unknown from the carcinoma of unknown primary. J Clin Oncol. 2013;31:174–5.
20. Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10:e1004135.
21. Xiao J-C, Ruck P, Adam A, Wang T-X, Kaiserling E. Small epithelial cells in human liver cirrhosis exhibit features of hepatic stem-like cells: immunohistochemical, electron microscopic and immunoelectron microscopic findings. Histopathology. 2003;42:141–9.
22. Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013;31:217–23.
23. Monzon FA, Lyons-Weiler M, Buturovic LJ, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol. 2009;27:2503–8.
24. Varadhachary G. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling. Clin Cancer Res. 2013;19:4027–33.